Chardan bullish on vintafolide as Endocyte slides

Chardan Capital starts Endocyte (ECYT -3.7%) at Buy with a $20 price target on the familiar "vintafolide/ etarfolatide alone are worth around $6/share" thesis.

"We expect ... positive data from the ongoing Phase 3 trial in folate receptor -positive ovarian cancer and in a randomized Phase 2 trial in FR (100%) NSCLC to drive significant upside," analyst Ling Wang says.

Investors have been reluctant to jump in however, with the stock off some 28% since hitting a 52-week high at the beginning of August.

For more, see SA contributor Benjamin Paluch's recent article.

Comments (1)
  • TruffelPig
    , contributor
    Comments (4207) | Send Message
    My most favorite biotech company :). I bought shares at $3, $7, $12.5, $14.5. Right now I am waiting how this drama in Washington works out - I think the current price is a clear buying op but I already have so many shares. Still, I will buy more if this drops further.
    30 Sep 2013, 02:31 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs